Free Trial

Innoviva (INVA) Competitors

Innoviva logo
$19.37 -0.06 (-0.31%)
Closing price 04:00 PM Eastern
Extended Trading
$19.36 -0.01 (-0.05%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INVA vs. ALKS, LGND, FOLD, BCRX, MNKD, CLDX, NVAX, DVAX, OPK, and GERN

Should you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Celldex Therapeutics (CLDX), Novavax (NVAX), Dynavax Technologies (DVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry.

Innoviva vs. Its Competitors

Innoviva (NASDAQ:INVA) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

99.1% of Innoviva shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 2.3% of Innoviva shares are held by company insiders. Comparatively, 4.4% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Innoviva presently has a consensus price target of $42.75, suggesting a potential upside of 120.70%. Alkermes has a consensus price target of $41.85, suggesting a potential upside of 55.16%. Given Innoviva's stronger consensus rating and higher probable upside, equities research analysts clearly believe Innoviva is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innoviva
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Alkermes
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92

Alkermes has a net margin of 23.15% compared to Innoviva's net margin of 10.44%. Alkermes' return on equity of 24.86% beat Innoviva's return on equity.

Company Net Margins Return on Equity Return on Assets
Innoviva10.44% 18.67% 9.92%
Alkermes 23.15%24.86%17.14%

In the previous week, Alkermes had 21 more articles in the media than Innoviva. MarketBeat recorded 27 mentions for Alkermes and 6 mentions for Innoviva. Innoviva's average media sentiment score of 1.64 beat Alkermes' score of 0.63 indicating that Innoviva is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Innoviva
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Alkermes
5 Very Positive mention(s)
3 Positive mention(s)
13 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Alkermes has higher revenue and earnings than Innoviva. Alkermes is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innoviva$358.71M3.40$23.39M$0.3162.48
Alkermes$1.56B2.86$367.07M$2.0812.97

Innoviva has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Summary

Alkermes beats Innoviva on 11 of the 17 factors compared between the two stocks.

Get Innoviva News Delivered to You Automatically

Sign up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INVA vs. The Competition

MetricInnovivaLarge Cap Pharma IndustryMedical SectorNASDAQ Exchange
Market Cap$1.22B$254.32B$5.79B$10.15B
Dividend YieldN/A2.70%5.69%4.61%
P/E Ratio62.4930.4874.5925.92
Price / Sales3.404.70449.5483.33
Price / Cash5.6713.6737.0859.91
Price / Book1.7618.6612.156.29
Net Income$23.39M$8.49B$3.28B$270.85M
7 Day Performance-5.42%-1.10%0.98%3.36%
1 Month Performance-3.58%5.16%7.20%6.41%
1 Year Performance-1.22%-8.95%63.06%28.26%

Innoviva Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INVA
Innoviva
4.8927 of 5 stars
$19.37
-0.3%
$42.75
+120.7%
+0.2%$1.22B$358.71M62.49100Positive News
Short Interest ↓
ALKS
Alkermes
4.5541 of 5 stars
$28.45
-5.0%
$41.31
+45.2%
+4.3%$4.94B$1.56B13.681,800Trending News
Analyst Forecast
High Trading Volume
LGND
Ligand Pharmaceuticals
4.2344 of 5 stars
$165.86
-0.5%
$176.50
+6.4%
+62.1%$3.27B$187.58M-41.4780Short Interest ↑
FOLD
Amicus Therapeutics
3.9687 of 5 stars
$7.98
-0.1%
$16.00
+100.5%
-28.8%$2.46B$571.16M-66.49480Positive News
BCRX
BioCryst Pharmaceuticals
4.2643 of 5 stars
$8.19
-1.0%
$16.70
+103.9%
+4.4%$1.74B$450.71M-45.50530Positive News
MNKD
MannKind
4.4259 of 5 stars
$5.57
+0.5%
$11.17
+100.5%
-11.6%$1.70B$285.50M50.64400Positive News
Short Interest ↓
CLDX
Celldex Therapeutics
2.393 of 5 stars
$23.40
+2.3%
$46.67
+99.4%
-39.5%$1.52B$7.02M-7.77150Positive News
NVAX
Novavax
4.4804 of 5 stars
$7.73
-2.2%
$14.29
+84.8%
-32.6%$1.28B$1.08B3.391,990Positive News
DVAX
Dynavax Technologies
4.4635 of 5 stars
$9.70
-3.6%
$24.33
+150.9%
-10.7%$1.18B$316.27M-21.09350Positive News
OPK
OPKO Health
4.4969 of 5 stars
$1.42
+5.2%
$2.75
+93.7%
-8.3%$1.07B$713.10M-5.682,997
GERN
Geron
3.1384 of 5 stars
$1.37
-2.1%
$3.79
+176.3%
-69.9%$893.22M$164.45M-10.5470Positive News

Related Companies and Tools


This page (NASDAQ:INVA) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners